Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shweta Joshi

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Plos One|March 4, 2016
PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven MedulloblastomaAlok R Singh, Shweta Joshi, Muamera Zulcic, et al.
American Journal of Hematology|August 11, 2015
Vascular remodeling underlies rebleeding in hemophilic arthropathyVikas Bhat, Merissa Olmer, Shweta Joshi, et al.
Oncotarget|September 9, 2017
Association of high microvessel α<sub>v</sub>β<sub>3</sub> and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126Anat Erdreich-Epstein, Alok R Singh, Shweta Joshi, et al.
Molecular Cancer Therapeutics|January 25, 2020
Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor ImmunosuppressionShweta Joshi, Kevin X Liu, Muamera Zulcic, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Plos One|March 4, 2016
PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven MedulloblastomaAlok R Singh, Shweta Joshi, Muamera Zulcic, et al.
American Journal of Hematology|August 11, 2015
Vascular remodeling underlies rebleeding in hemophilic arthropathyVikas Bhat, Merissa Olmer, Shweta Joshi, et al.
Oncotarget|September 9, 2017
Association of high microvessel α<sub>v</sub>β<sub>3</sub> and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126Anat Erdreich-Epstein, Alok R Singh, Shweta Joshi, et al.
Molecular Cancer Therapeutics|January 25, 2020
Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor ImmunosuppressionShweta Joshi, Kevin X Liu, Muamera Zulcic, et al.
Pageof 5